🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

69 results for “Second” Clear

  1. ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab

    Second Affiliated Hospital of Soochow University

    Liver Cancer

    phase 2 small molecule active

    1 trial

  2. A Study to Learn How Different Forms of The Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults

    Pfizer Australia Pty Ltd

    Primary and secondary hypertension, and heart failure

    phase 1 other active

    1 trial

  3. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  4. Allogeneic (MSC's) Application to the Burn Wounds

    United Therapeutics Europe Ltd

    Skin Burn Degree Second

    phase 1 mab completed

    1 trial

  5. CART19 cell and auto-HSCT

    Shenzhen Second People's Hospital

    Leukemia, Lymphocytic, Acute, B-Cell

    phase 1 mab active

    1 trial

  6. Group A Deactivated TENS with beeping sound (15-second interval)

    United Therapeutics Europe Ltd

    Healthy

    phase 1 other completed

    1 trial

  7. Cinacalcet HCl

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hyperparathyroidism; Secondary, Renal

    approved small molecule completed

    1 trial

  8. Combination Cinacalcet with Vitamin D analogue

    Hospital Authority, Hong Kong

    Secondary Hyperparathyroidism

    approved small molecule active

    1 trial

  9. HYDROCORTISONE PH. EUR., HYDROCORTISONE PH. EUR.

    The George Institute

    Adrenal hyperplasia or isolated primary adrenal insufficiency or panhypopituitarism (secondary or tertiary adrenal insufficiency).

    approved small molecule active

    1 trial

  10. Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets

    Verona Pharma Ireland Limited

    patients with secondary progressive MS

    approved small molecule active

    1 trial

  11. RIVAROXABAN , RIVAROXABAN, RIVAROXABAN

    Pari Pharma GmbH

    Patients with excessive supraventricular ectopies or short atrial runs (ESVEA) defined as ≥ 1% premature atrial contractions (PAC) /24 hours or any atrial runs ≥ 20 PACs (but shorter than 30 seconds) on a 24-hour Holter ECG monitoring and CHA2DS2VASC score ≥ 3. Patients with any atrial runs ≥ 20 PACs but shorter than 30 seconds on a 15-21 days Holter ECG monitoring and CHA2DS2VASC score ≥ 3 may also be included in the Short-Run trial.

    approved small molecule active

    1 trial

  12. Rivaroxaban 2.5 mg

    Second Xiangya Hospital of Central South University

    Acute Coronary Syndrome

    approved small molecule completed

    1 trial

  13. SALINE, TRANEXAMIC ACID

    Disc Medicine

    Slipped capital femoral epiphysis (SCFE), Legg-Calvé-Perthes Disease (LCPD), Neuromuscular conditions, Secondary hip dysplasia, Developmental dysplasia of the hip (DDH)

    approved small molecule active

    1 trial

  14. Vedolizumab

    Second Affiliated Hospital of Soochow University

    Ulcerative Colitis (UC)

    approved mab completed

    1 trial

  15. AIM-CHD Mobile Health Intervention

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Secondary Prevention of Coronary Heart Disease

    other completed

    1 trial

  16. Citalopram

    COGNITION THERAPEUTICS INC

    Antidepressive Agents, Second-Generation

    small molecule completed

    1 trial

  17. Conventional second-line therapy

    The First People's Hospital of Lianyungang

    Colorectal Cancer (CRC)

    other active

    1 trial

  18. Esketamine, Sulfentanil or/and Remifentanil

    Second Affiliated Hospital of Soochow University

    Opioid Analgesic Adverse Reaction

    small molecule active

    1 trial

  19. Hydromorphone combined with ropivacaine

    Second Hospital of Jilin University

    Inguinal Hernia

    small molecule completed

    1 trial

  20. Inhaled corticosteriod/long-acting beta-agonist plus Montelukast

    Second Affiliated Hospital, School of Medicine, Zhejiang University

    Asthma

    small molecule active

    1 trial

  21. Linaclotide

    Second Affiliated Hospital of Xi'an Jiaotong University

    Bowel Preparation

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources